Speaker Profile
M.D., CEO, Heteron BIotechnologies,
Biography
Anastasia Rigas leads Heteron Biotechnologies in developing a clinical-stage breath diagnostics platform that leverages advanced machine learning to transform complex breath profilescontaining thousands of gases and VOCsinto precise, multi-indication diagnostics. Under her leadership, Heterons multidisciplinary team has applied and rigorously tested various models on proprietary datasets, achieving exceptionally high classification accuracy. This builds on prior peer-reviewed expertise now integrated in-house, positioning the platform to detect H. pylori for gastric cancer prevention, stratify metabolic syndrome risk, and enable future hepatic and performance health applications. The technology is advancing under FDA CDRH oversight with pivotal trials in preparation and secured by global PCT filings covering hardware, software, and disease-specific biomarkers. Passionate about shifting healthcare from reactive intervention to AI-driven prevention, Anastasia coordinates regulatory strategy, multi-center clinical design, and strategic partnerships to establish breath-based machine learning diagnostics as a new paradigm in accessible precision medicine
Talk
AI Breath Diagnostics for Early Disease Detection
Heterons multi-gas breath platform integrates proprietary machine learning to classify complex VOC profiles, enabling accurate point-of-care diagnosis of H. pylori, Celiac and metabolic syndrome. Advancing under FDA CDRH oversight with global PCT protection, it delivers scalable, reimbursable AI-driven diagnostics that identify earlier-stage disease, improving outcomes through timely, informed clinical intervention.
AI and Data Sciences Showcase:
Heteron BIotechnologies,
Heteron is a clinical-stage diagnostics company advancing a multi-gas breath analysis platform that uses proprietary machine learning to deliver precise, multi-indication detection from complex breath samples. The technology targets scalable, reimbursable screening for gastric cancer prevention, metabolic syndrome, Celiac Disease and broader preventive care.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
